Improved heart function with sacubitril/valsartan was linked to enhanced ventricular-arterial coupling and cardiac efficiency ...

Sacubitril/valsartan treatment, however, was significantly associated with an 85% increased likelihood of kidney function recovery, Wei Chen, MD, PhD, of The First Affiliated Hospital, Sun Yat-sen ...

Over the past few years, sacubitril/valsartan has made its way onto heart failure guidelines for adults, 2 backed by data from the PARADIGM-HF study (NCT01035255), in which it demonstrated a 21% ...

The analysis included 1910 patients: 797 (42%) were classified as low KDIGO risk, 609 (32%) as moderate risk, and 504 (26%) as high/very high risk. Mean ages were 64.6±10.0 years in the low risk ...

Guidelines recommend consideration of sacubitril/valsartan to reduce hospitalizations in patients with heart failure with preserved EF (HFpEF; EF >50%) and/or mildly reduced EF (HFmrEF; EF 41-49%).

Sacubitril/valsartan leads to greater reduction in plasma NT-proBNP levels compared to valsartan alone after stabilization for worsening heart failure in patients with an ejection fraction (EF ...

Declines in renal function observed during transition from a renin-angiotensin system inhibitor to sacubitril/valsartan for HF are variable but usually small and partially recoverable for most ...

Sacubitril/valsartan does not change cognitive function, compared with valsartan, in patients with heart failure and mildly reduced or preserved ejection fraction, according to late breaking ...

Use of sacubitril/valsartan was also shown to not increase risks of hypotension, hyperkalemia, angioedema, and cough, but it did significantly improve distance on the 6-minute walk test.